|
Apr 30
|
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
|
|
Apr 28
|
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
|
|
Mar 12
|
3 Promising ASX Penny Stocks With Market Caps Over A$20M
|
|
Mar 10
|
Alterity Therapeutics (ATHE): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Oct 14
|
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
|
|
Oct 11
|
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
|
|
Jul 24
|
Alterity Therapeutics to Present at MST Financial Webinar
|
|
Feb 6
|
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
|
|
Jan 29
|
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
|
|
Dec 21
|
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 4
|
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
|
|
Dec 4
|
Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data
|
|
Dec 4
|
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
|
|
Nov 27
|
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy
|
|
Nov 16
|
Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
|
|
Apr 26
|
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
|